GLPwatch
Zepbound for Depression
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCZepbound (tirzepatide) is not FDA-approved for depression. Research includes pharmacovigilance analyses and reviews reporting psychiatric adverse events and signals related to tirzepatide, but these do not establish efficacy or approval for this use.
AI summary of the sources below.
| Drug | Zepbound (tirzepatide) |
|---|---|
| Condition | Depression |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Zepbound is not FDA-approved for depression; the research below reflects investigational or off-label study only.
Research on tirzepatide for depression (4)
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.
- Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.